Compare JUBILANT LIFE SCIENCES with Biocon Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

JUBILANT LIFE SCIENCES vs BIOCON - Comparison Results

BIOCON  
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    JUBILANT LIFE SCIENCES BIOCON JUBILANT LIFE SCIENCES/
BIOCON
 
P/E (TTM) x 12.6 31.6 39.8% View Chart
P/BV x 2.4 4.1 57.7% View Chart
Dividend Yield % 0.6 0.2 262.5%  

Financials

 JUBILANT LIFE SCIENCES   BIOCON
EQUITY SHARE DATA
    JUBILANT LIFE SCIENCES
Mar-19
BIOCON
Mar-19
JUBILANT LIFE SCIENCES/
BIOCON
5-Yr Chart
Click to enlarge
High Rs898707 127.0%   
Low Rs618554 111.5%   
Sales per share (Unadj.) Rs572.091.9 622.4%  
Earnings per share (Unadj.) Rs36.216.7 216.8%  
Cash flow per share (Unadj.) Rs59.524.2 246.2%  
Dividends per share (Unadj.) Rs4.501.00 450.0%  
Dividend yield (eoy) %0.60.2 374.5%  
Book value per share (Unadj.) Rs301.9101.6 297.1%  
Shares outstanding (eoy) m159.28600.00 26.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.36.9 19.3%   
Avg P/E ratio x20.937.7 55.4%  
P/CF ratio (eoy) x12.726.1 48.8%  
Price / Book Value ratio x2.56.2 40.5%  
Dividend payout %12.46.0 207.6%   
Avg Mkt Cap Rs m120,694378,330 31.9%   
No. of employees `0002.46.1 39.0%   
Total wages/salary Rs m19,26011,653 165.3%   
Avg. sales/employee Rs Th38,120.68,994.3 423.8%   
Avg. wages/employee Rs Th8,058.41,900.7 424.0%   
Avg. net profit/employee Rs Th2,414.31,635.3 147.6%   
INCOME DATA
Net Sales Rs m91,10855,144 165.2%  
Other income Rs m3571,444 24.8%   
Total revenues Rs m91,46656,588 161.6%   
Gross profit Rs m17,39015,883 109.5%  
Depreciation Rs m3,7094,478 82.8%   
Interest Rs m2,198709 310.0%   
Profit before tax Rs m11,84012,140 97.5%   
Minority Interest Rs m09 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-2,8020-   
Tax Rs m3,2682,123 153.9%   
Profit after tax Rs m5,77010,026 57.6%  
Gross profit margin %19.128.8 66.3%  
Effective tax rate %27.617.5 157.8%   
Net profit margin %6.318.2 34.8%  
BALANCE SHEET DATA
Current assets Rs m45,84848,228 95.1%   
Current liabilities Rs m20,89730,376 68.8%   
Net working cap to sales %27.432.4 84.6%  
Current ratio x2.21.6 138.2%  
Inventory Days Days5768 83.2%  
Debtors Days Days5186 59.6%  
Net fixed assets Rs m65,49864,130 102.1%   
Share capital Rs m1593,000 5.3%   
"Free" reserves Rs m47,93057,980 82.7%   
Net worth Rs m48,08960,980 78.9%   
Long term debt Rs m42,42915,766 269.1%   
Total assets Rs m114,685121,924 94.1%  
Interest coverage x6.418.1 35.2%   
Debt to equity ratio x0.90.3 341.3%  
Sales to assets ratio x0.80.5 175.6%   
Return on assets %6.98.8 78.9%  
Return on equity %12.016.4 73.0%  
Return on capital %12.416.8 74.1%  
Exports to sales %028.1 0.0%   
Imports to sales %018.9 0.0%   
Exports (fob) Rs mNA15,506 0.0%   
Imports (cif) Rs mNA10,399 0.0%   
Fx inflow Rs m12,42215,506 80.1%   
Fx outflow Rs m17,22710,399 165.7%   
Net fx Rs m-4,8055,107 -94.1%   
CASH FLOW
From Operations Rs m11,21511,546 97.1%  
From Investments Rs m-10,118-7,138 141.8%  
From Financial Activity Rs m6,574-2,417 -272.0%  
Net Cashflow Rs m7,6122,103 362.0%  

Share Holding

Indian Promoters % 45.6 40.4 112.9%  
Foreign collaborators % 3.5 20.6 17.0%  
Indian inst/Mut Fund % 8.7 8.4 103.6%  
FIIs % 21.2 10.7 198.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.1 19.9 106.0%  
Shareholders   23,815 109,995 21.7%  
Pledged promoter(s) holding % 15.9 0.0 39,625.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare JUBILANT LIFE SCIENCES With:   ABBOTT INDIA  NATCO PHARMA  AJANTA PHARMA  PIRAMAL ENTERPRISES  ALKEM LABORATORIES  

Compare JUBILANT LIFE SCIENCES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 143 Points Lower; Banking and Finance Stocks Witness Selling(Closing)

Indian share markets witnessed selling pressure throughout the day today, tracking weak global cues as coronavirus cases continue to surge across the world.

Related Views on News

JUBILANT LIFE SCIENCES Announces Quarterly Results (4QFY20); Net Profit Up 358.8% (Quarterly Result Update)

Jun 1, 2020 | Updated on Jun 1, 2020

For the quarter ended March 2020, JUBILANT LIFE SCIENCES has posted a net profit of Rs 3 bn (up 358.8% YoY). Sales on the other hand came in at Rs 24 bn (up 0.2% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (3QFY20); Net Profit Down 24.0% (Quarterly Result Update)

Feb 1, 2020 | Updated on Feb 1, 2020

For the quarter ended December 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (down 24.0% YoY). Sales on the other hand came in at Rs 23 bn (down 2.6% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

BIOCON Announces Quarterly Results (3QFY20); Net Profit Up 1.2% (Quarterly Result Update)

Jan 24, 2020 | Updated on Jan 24, 2020

For the quarter ended December 2019, BIOCON has posted a net profit of Rs 2 bn (up 1.2% YoY). Sales on the other hand came in at Rs 17 bn (up 13.5% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (2QFY20); Net Profit Down 30.5% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, BIOCON has posted a net profit of Rs 3 bn (down 30.5% YoY). Sales on the other hand came in at Rs 16 bn (up 19.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (2QFY20); Net Profit Up 18.9% (Quarterly Result Update)

Oct 31, 2019 | Updated on Oct 31, 2019

For the quarter ended September 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (up 18.9% YoY). Sales on the other hand came in at Rs 23 bn (down 0.2% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

More Views on News

Most Popular

How to Find the Best Stocks for Day Trading - 1(Fast Profits Daily)

Jul 2, 2020

In the first of two videos, I'll show you how to identify the best stocks for intraday trading.

Two Agri Stocks Are Likely to Outperform Even in this Market(Profit Hunter)

Jul 2, 2020

Why we have recommended two agriculture stocks for our Hidden Treasure subscribers. Read on...

A Warning for Traders: Don't Get Addicted to Hopium(Fast Profits Daily)

Jun 30, 2020

If you are a trader, you must watch out for this dangerous addiction.

Smallcaps Are in a Sweet Spot Again: Are You Buying?(Profit Hunter)

Jul 3, 2020

This is why I believe smallcaps are the place to be in the near future.

More

India's #1 Trader
Reveals His Secrets

The Secret to Increasing Your Trading Profits Today
Get this Special Report, The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

JUBILANT LIFE SCIENCES SHARE PRICE


Jul 10, 2020 (Close)

TRACK JUBILANT LIFE SCIENCES

  • Track your investment in JUBILANT LIFE SCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON JUBILANT LIFE SCIENCES

JUBILANT LIFE SCIENCES 8-QTR ANALYSIS

COMPARE JUBILANT LIFE SCIENCES WITH

MARKET STATS